Lyra Therapeutics, Inc. (LYRA)
| Market Cap | 161.35M |
| Revenue (ttm) | 5.65M |
| Net Income (ttm) | -42.72M |
| Shares Out | 31.83M |
| EPS (ttm) | -3.35 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 14,508 |
| Open | 4.83 |
| Previous Close | 4.88 |
| Day's Range | 4.83 - 5.26 |
| 52-Week Range | 3.30 - 9.98 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 22.10 (+335.9%) |
| Earnings Date | May 10, 2022 |
About LYRA
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase ...
Financial Performance
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for LYRA stock is "Buy." The 12-month stock price forecast is 22.1, which is an increase of 335.90% from the latest price.
News
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
Lyra Therapeutics, Inc. (LYRA) delivered earnings and revenue surprises of 41.30% and 114.68%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update
In April 2022, secured $100.5 million in gross proceeds in an at-the-market, private placement of common stock that is expected to support two pivotal data readouts; cash runway extended until mid-2024 ...
Lyra Therapeutics to Present at Upcoming Investor Conferences
WATERTOWN, Mass. , May 5, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and ...
Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusiti...
LYR-210 provided up to 24 weeks of clinically meaningful global symptom improvement in CRS patients LYR-210 achieved significant improvement in each CRS symptom subdomain of the SNOT-22 compared to cont...
7 Stocks to Watch for Major Insider Trading Clues
These seven stocks show varying degrees of insider trading, which can provide a hint regarding each company or fund's performance. The post 7 Stocks to Watch for Major Insider Trading Clues appeared fir...
Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chroni...
WATERTOWN, Mass. , April 25, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, a...
Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022
LYR-210 Data on Impact of Long-Acting Implantable Corticosteroid Matrices in Patients with CRS Selected as a Top Clinical Abstract Both Presentations Demonstrate Potential Benefit of LYR-210 to Chronic ...
Lyra Therapeutics Announces Closing of $100.5 Million Private Placement
Private placement priced at-the-market under Nasdaq rules Proceeds to support Lyra's ongoing clinical development of LYR-210 and LYR-220 Proceeds, combined with existing cash and expected milestone paym...
Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stocks Are Soaring Friday
We're diving into the top penny stocks for today in our market update for Friday with all the latest news that's moving shares! The post Top Penny Stocks Today: Why ATER, BFRI, NDRA, MDVL and LYRA Stock...
Lyra Therapeutics Stock Surges On Equity Raise Of $100M
Lyra Therapeutics Inc (NASDAQ: LYRA) has announced a private placement of approximately $100.5 million. The Company has offered 18.8 million common shares at $4.22 per share and pre-funded warrants to p...
Lyra Therapeutics Announces $100.5 Million Private Placement
WATERTOWN, Mass., April 8, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) today announced that it has entered into a securities purchase agreement to sell securities in a private placement ...
Lyra Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
WATERTOWN, Mass., March 9, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained and ...
Lyra Therapeutics Appoints Jim Tobin to Board of Directors
WATERTOWN, Mass., March 7, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and...
Lyra Therapeutics Announces First Patient Dosed in Pivotal ENLIGHTEN I Clinical Trial of LYR-210 in Chronic Rhinosinu...
WATERTOWN, Mass., Feb. 28, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and...
Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman
WATERTOWN, Mass., Feb. 17, 2022 /PRNewswire/ -- Lyra Therapeutics today announced the appointment of Harlan W.
Lyra Therapeutics Kickstarts LYR-210 Pivotal Program in Surgically Naïve Chronic Rhinosinusitis Patients
Lyra Therapeutics Inc (NASDAQ: LYRA) has initiated its Phase 3 ENLIGHTEN I trial of LYR-210 in adult, surgically naïve chronic rhinosinusitis (CRS) patients. LYR-210 is designed to be administered in a ...
Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhino...
WATERTOWN, Mass., Jan. 24, 2022 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and...
Lyra Therapeutics to Present at Upcoming Virtual Investor Conferences
WATERTOWN, Mass., Nov. 11, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and...
Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
WATERTOWN, Mass., Nov. 9, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and ...
Lyra Therapeutics to Report Third Quarter 2021 Financial Results on November 9
WATERTOWN, Mass., Nov. 2, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and ...
Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTE...
WATERTOWN, Mass., Oct. 4, 2021 /PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained, and ...
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology
LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis Pa...
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New...
LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer
Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role Seasoned investment banking executive brings extensive finance, partnering and M&A experience to...
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ ...
Results demonstrate XTreo™ technology platform provides targeted and sustained dosing of anti-inflammatory medication